SG11202012373YA - Oncology treatments using zinc agents - Google Patents

Oncology treatments using zinc agents

Info

Publication number
SG11202012373YA
SG11202012373YA SG11202012373YA SG11202012373YA SG11202012373YA SG 11202012373Y A SG11202012373Y A SG 11202012373YA SG 11202012373Y A SG11202012373Y A SG 11202012373YA SG 11202012373Y A SG11202012373Y A SG 11202012373YA SG 11202012373Y A SG11202012373Y A SG 11202012373YA
Authority
SG
Singapore
Prior art keywords
oncology treatments
zinc
agents
zinc agents
oncology
Prior art date
Application number
SG11202012373YA
Other languages
English (en)
Inventor
Jinhyuk Fred Chung
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10201805412TA external-priority patent/SG10201805412TA/en
Priority claimed from SG10201811577TA external-priority patent/SG10201811577TA/en
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Publication of SG11202012373YA publication Critical patent/SG11202012373YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202012373YA 2018-06-22 2019-06-21 Oncology treatments using zinc agents SG11202012373YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201805412TA SG10201805412TA (en) 2018-06-22 2018-06-22 Zinc agents for monotherapy and combination therapy oncology treatments
SG10201811577TA SG10201811577TA (en) 2018-12-24 2018-12-24 Oncology treatments using zinc agents
PCT/SG2019/050308 WO2019245458A1 (en) 2018-06-22 2019-06-21 Oncology treatments using zinc agents

Publications (1)

Publication Number Publication Date
SG11202012373YA true SG11202012373YA (en) 2021-01-28

Family

ID=67108114

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012373YA SG11202012373YA (en) 2018-06-22 2019-06-21 Oncology treatments using zinc agents

Country Status (10)

Country Link
US (1) US20210128609A1 (ko)
EP (1) EP3810154A1 (ko)
JP (1) JP2021527707A (ko)
KR (1) KR20210024065A (ko)
CN (1) CN112584842A (ko)
AU (1) AU2019290345A1 (ko)
CA (1) CA3104612A1 (ko)
MX (1) MX2020013883A (ko)
SG (1) SG11202012373YA (ko)
WO (1) WO2019245458A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
JP2024510327A (ja) * 2021-03-18 2024-03-06 ジロニックス・ピーティーイー.リミテッド 医薬ポリマーコンジュゲート

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141110A2 (en) 2007-05-09 2008-11-20 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
US9132098B2 (en) 2013-03-28 2015-09-15 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
JP6262334B2 (ja) 2013-04-26 2018-01-17 日東電工株式会社 ポリ(グルタミル−グルタマート)結合体を製造するための大規模な方法
CA3034266A1 (en) * 2016-08-19 2018-02-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201609131YA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer

Also Published As

Publication number Publication date
KR20210024065A (ko) 2021-03-04
CN112584842A (zh) 2021-03-30
JP2021527707A (ja) 2021-10-14
CA3104612A1 (en) 2019-12-26
WO2019245458A1 (en) 2019-12-26
EP3810154A1 (en) 2021-04-28
AU2019290345A1 (en) 2021-01-07
US20210128609A1 (en) 2021-05-06
MX2020013883A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL277336A (en) combined treatment
GB201804255D0 (en) Macrophage-based therapy
GB201814169D0 (en) Blockchain autonoumous agents
GB201800274D0 (en) Novel treatments
GB201820660D0 (en) Cancer treatments
GB201805816D0 (en) Therapeutic agents
GB201819853D0 (en) Therapy
IL280968A (en) Combined treatment
IL279908A (en) Combined treatment
GB201808564D0 (en) Treatments
SG11202012373YA (en) Oncology treatments using zinc agents
SG10201811577TA (en) Oncology treatments using zinc agents
ZA202006321B (en) Treatments
IL280729A (en) Combined treatment
GB2585661B (en) Radiotherapy device
SG10201805412TA (en) Zinc agents for monotherapy and combination therapy oncology treatments
GB2590457B (en) Radiotherapy device
GB201820215D0 (en) Treatments etc
GB201807415D0 (en) Cancer treatments
GB201802264D0 (en) Cancer treatments
GB201902400D0 (en) Radiotherapy device
GB201801982D0 (en) Novel treatments
GB201820162D0 (en) Therapeutic agents